皓宸医疗
(002622)
| 流通市值：17.39亿 | | | 总市值：17.39亿 |
| 流通股本：8.40亿 | | | 总股本：8.40亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 119,306,297.16 | 146,388,361.1 | 155,890,319.05 | 144,861,149.59 |
| 应收票据及应收账款 | 34,800,583.34 | 37,296,995.44 | 33,733,565.77 | 32,166,172.21 |
| 其中：应收票据 | 2,584,312.56 | 5,547,020.71 | 11,275,975.23 | 7,961,041 |
| 应收账款 | 32,216,270.78 | 31,749,974.73 | 22,457,590.54 | 24,205,131.21 |
| 预付款项 | 17,477,928.39 | 12,959,242.62 | 33,407,091.96 | 40,705,492.62 |
| 其他应收款合计 | 42,602,188.81 | 41,050,442.15 | 44,951,545.73 | 42,496,457.56 |
| 应收股利 | 22,700,000 | 22,700,000 | 22,700,000 | 22,700,000 |
| 存货 | 72,975,282.09 | 62,143,075.81 | 66,346,229.75 | 57,729,125.32 |
| 其他流动资产 | 1,783,083.18 | 2,234,778.11 | 1,708,763.5 | 1,685,341.94 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 289,659,547.68 | 302,787,079.94 | 339,431,839.66 | 323,038,063.14 |
| 非流动资产: | | | | |
| 长期股权投资 | 486,739,590.13 | 476,480,000 | 598,138,357.15 | 592,859,048.86 |
| 其他权益工具投资 | 11,800,000 | 11,800,000 | 36,321,780 | 36,321,780 |
| 投资性房地产 | 32,271,733.5 | 32,615,113.92 | 32,958,494.34 | 33,301,874.76 |
| 固定资产 | 168,445,959.63 | 170,827,939 | 171,708,040.42 | 173,621,855.87 |
| 在建工程 | - | 79,530.81 | - | - |
| 使用权资产 | 171,022,565.84 | 178,087,342.8 | 141,527,463.95 | 149,499,973.97 |
| 无形资产 | 47,055,234.2 | 47,795,049.69 | 48,045,715.76 | 48,219,321.35 |
| 商誉 | 199,672,759.15 | 199,672,759.15 | 199,672,759.15 | 199,672,759.15 |
| 长期待摊费用 | 65,664,483.43 | 65,850,399.03 | 54,729,442.3 | 54,737,244.42 |
| 递延所得税资产 | 52,231,854.31 | 49,895,385.23 | 70,206,167.95 | 70,082,022.5 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 1,234,904,180.19 | 1,233,103,519.63 | 1,353,308,221.02 | 1,358,315,880.88 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 1,524,563,727.87 | 1,535,890,599.57 | 1,692,740,060.68 | 1,681,353,944.02 |
| 流动负债: | | | | |
| 短期借款 | 113,759,100 | 120,773,120.69 | 142,021,388.89 | 142,004,812.5 |
| 应付票据及应付账款 | 70,589,137.25 | 60,113,853.34 | 67,316,252.37 | 81,950,854.35 |
| 应付账款 | 70,589,137.25 | 60,113,853.34 | 67,316,252.37 | 81,950,854.35 |
| 预收款项 | - | - | 19,000,000 | 19,000,000 |
| 合同负债 | 155,882,641.84 | 154,090,483.06 | 183,066,188.45 | 171,747,052.5 |
| 应付职工薪酬 | 25,517,424.41 | 27,553,688.82 | 24,300,463.7 | 22,174,639.69 |
| 应交税费 | 1,967,432.36 | 5,856,335.34 | 1,687,916.25 | 2,928,188.25 |
| 其他应付款合计 | 305,231,713.71 | 302,013,189.53 | 282,501,658.01 | 278,070,565.91 |
| 其中:应付利息 | 56,137,142.38 | 51,644,512.99 | 46,392,267.37 | 41,733,785.71 |
| 一年内到期的非流动负债 | 219,778,047.85 | 217,892,737.69 | 225,046,780.49 | 234,428,333.8 |
| 其他流动负债 | 1,153,380.27 | 3,463,756.49 | 1,726,947.92 | 1,368,315.7 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 893,878,877.69 | 891,757,164.96 | 946,667,596.08 | 953,672,762.7 |
| 非流动负债: | | | | |
| 租赁负债 | 149,550,046.25 | 161,343,499.43 | 122,029,698.43 | 127,635,916 |
| 预计负债 | - | - | - | 35,637.09 |
| 递延收益 | 8,996,926.31 | 9,108,673.49 | 9,220,420.67 | 9,332,167.85 |
| 递延所得税负债 | 8,353,396.98 | 8,538,301.7 | 8,833,861.05 | 9,087,747.42 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 166,900,369.54 | 178,990,474.62 | 140,083,980.15 | 146,091,468.36 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 1,060,779,247.23 | 1,070,747,639.58 | 1,086,751,576.23 | 1,099,764,231.06 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 840,000,000 | 840,000,000 | 840,000,000 | 840,000,000 |
| 资本公积 | 21,685,838.28 | 21,685,838.28 | 18,824,244.31 | 18,824,244.31 |
| 其他综合收益 | -50,697,366.87 | -51,597,708.41 | -107,492,369.78 | -108,480,125.14 |
| 盈余公积 | 40,813,718.28 | 40,813,718.28 | 51,431,341.54 | 51,431,341.54 |
| 未分配利润 | -420,259,460.43 | -418,117,817.07 | -211,872,577.99 | -220,573,561.05 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 431,542,729.26 | 432,784,031.08 | 590,890,638.08 | 581,201,899.66 |
| 少数股东权益 | 32,241,751.38 | 32,358,928.91 | 15,097,846.37 | 387,813.3 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 463,784,480.64 | 465,142,959.99 | 605,988,484.45 | 581,589,712.96 |
| 负债和股东权益合计 | 1,524,563,727.87 | 1,535,890,599.57 | 1,692,740,060.68 | 1,681,353,944.02 |
| 公告日期 | 2024-04-29 | 2024-04-29 | 2023-10-31 | 2023-08-31 |
| 审计意见(境内) | | 带强调事项段的无保留意见 | | |